The Investment Landscape
The appeal of non-invasive neurotech to investors is multifaceted. Kerry Baldwin, co-founder of U.K.-based deep-tech investor IQ capital, which has backed Neurovalens, describes the opportunity as "massive." The relatively low capital requirements for development, compared to invasive technologies or traditional pharmaceutical research, make it an attractive proposition for early-stage investors.